Stay current on emerging evidence in transplantation and cellular therapy. At next week's ASTCT Pharmacy Journal Club, presenters will review data from the ATLAS trial and ZUMA-2 Cohort 3. Register: learn.astct.org/products/ast...
ASTCT
@astct.bsky.social
The American Society for Transplantation and Cellular Therapy astct.org
📣 Call for speakers! ASTCT is seeking speakers for the 2026 virtual Clinical Education Conference, taking place Oct. 22-23. The Planning Committee welcomes presenters from a breadth of speaker experiences and backgrounds. Learn more and apply: ow.ly/TcRL50YCYCF
Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field. @huntsmancancer.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology www.onclive.com/view/orca-t-...
Orca-T Diversifies Well-Tolerated Post-Transplant Treatment Options for Hematologic Malignancies | OncLive
Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.
onclive.com
Today, Oncology Pharmacist Day, ASTCT recognizes and sends appreciation to our dedicated pharmacists in oncology who work tirelessly to advance patient care and improve outcomes.
📣 Final chance to save $50 on #SciMeeting26 If you are looking for high-value scientific exchange, direct access to peers and a setting built for discovery, this is the meeting to attend. Register here ⬇️ https://www.ebmt.org/events/5th-joint-astct-ebmt-basic-and-translational-scientific-meeting
Time is running out to apply for ASTCT's Clinical Research Training Course (CRTC)! Geared toward fellows and junior faculty, CRTC covers research principles and how to take findings from the lab to the clinic. Learn more and apply before March 15: ow.ly/hwUi50Yogez
Join the ASTCT Pharmacy SIG on a discussion on Orca-T vs alloHCT and teclistamab plus daratumumab in r/r multiple myeloma. Register today: learn.astct.org/products/ast... #CART #celltherapy
💻 Free Webinar: Join the EBMT Pharmacist Committee and the ASTCT Pharmacy SIG for our second joint virtual journal club, this time on model-based dosing of ATG. 🗓️ Thursday, 29 January ⏰ 16:00-17:00 CET Discover more and sign up today: www.ebmt.org/pharmacists-... @astct.bsky.social
Our expert panel led by Roisin O'Cearbhaill & @marcoruella.bsky.social will discuss cellular IO at ASTCT's #Tandem26 Feb. 5. Explore the latest breakthroughs and clinical advances in cellular IO during this joint session from SITC and ASTCT. Learn more: https://ow.ly/2cEZ50XSyNg
Only ~20% of eligible patients receive CAR T therapy. Access shouldn’t depend on zip code. On #WorldCancerDay, take steps toward change for community-based care expansion. Act now by watching the full CME program with our partners @aacicancer.bsky.social & @astct.bsky.social 👉 bit.ly/3Zx8Jhd
We have touched down in Salt Lake City for the 2026 Transplantation & Cellular Therapy Meetings! We're gearing up for lots of excitement on the ground for the first day of the meeting today, so stay tuned! @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #hematology www.onclive.com/conference/tct
Congratulations to our 2026 Fellows of ASTCT (FASTCT) and past presidents Dr. Corey Cutler and Dr. Miguel-Angel Perales! #Tandem26 @drmiguelperales.bsky.social
As part of the GVHD Alliance community, ASTCT is proud to raise awareness and connect people with trusted GVHD resources. Learn more about GVHD and explore available resources as we prepare for GVHD Day on February 17. www.gvhdalliance.org/resources/ #GVHDDay #GVHDAlliance #StrongerThanGVHD
Join us on Jan. 21 for a webinar covering the latest guidelines for managing RSV & other paramyxoviruses. Experts will discuss special considerations for pediatric, cord blood, haploidentical & T cell-depleted HCT patients/CAR T recipients. Register for free: learn.astct.org/products/man...
Join global experts at the 2026 Tandem Meetings to explore the biological mechanisms driving acute and chronic GVHD, the latest clinical research and novel therapeutic approaches. Register today to attend these sessions: www.tandemmeetings.com
ASTCT is seeking passionate individuals to volunteer on a SIG or committee. This member-exclusive opportunity allows you to work with colleagues across the globe and make a direct impact on our organization. 🤝 Applications are due Friday, Nov. 7: https://ow.ly/qeKW50X5Pic
Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings. Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m
Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e
💡 Present your science on one of the biggest stages in hematopoietic cell transplantation, gene and cellular therapy. Submit an abstract by Oct. 9 and help shape the scientific program at the 2026 Tandem Meetings: ow.ly/wyrJ50WMqJY #Tandem26
Providers and Patients Are Encouraged to Remain Hypervigilant for Years After Transplant Regarding Potential Manifestations of Chronic GVHD — www.orionbrandstudio.com/supported-co...
Providers and Patients Are Encouraged to Remain Hypervigilant for Years After Transplant Regarding Potential Manifestations of Chronic GVHD - Orion Brand Studio
Chronic graft-versus-host disease (GVHD) occurs in up to 70% of patients who have undergone an allogeneic hematopoietic stem cell transplant and is the main cause of late, non-relapse mortality.1 It [...
orionbrandstudio.com
Nominations for the Society's premier awards close soon! These awards are given in recognition of individuals who have dedicated their time, knowledge & expertise to improve the work of the #HCT & cell therapy community. Nominate someone now: ow.ly/rNoR50WRuCk
ASTCT & CIBMTR are now accepting abstract submissions for #Tandem26! Share your HCT, cell therapy & gene therapy research with colleagues in the field. Submissions are due Oct. 9 & there will not be any deadline extensions. Learn more: ow.ly/wyrJ50WMqJY
ASTCT's New Investigator Awards (NIAs) are designed to encourage clinical and/or laboratory research by young investigators in the field of hematopoietic cell, cell therapy and/or gene therapy. Apply now or share this opportunity: ow.ly/Te6T50WuV9O
This 'Transplantation and Cellular Therapy' study identified advanced age, high comorbidities, UCB, & PTCy haploidentical HCT as factors significantly benefiting survival with LTV. The heterogeneity of LTV survival benefits showed the importance of personalized clinical decisions. ow.ly/LVe650WsP3E
🌟 For the first time, ASTCT is accepting abstracts to the Gene Therapy Summit! Be among the first researchers to share your gene therapy findings at this landmark meeting. Submit your abstract by Aug. 10: ow.ly/ocbb50Ws2MZ
Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/t7mO50Wkytj
Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/z5KT50Wkytl
ASTCT & CancerNetwork organized an X Space hosted by Rahul Banerjee; Taha Al-Juhaishi & Muhammad Salman Faisal to discuss key presentations and abstracts of interest at the 2025 ASCO Annual Meeting. Listen now to catch up on what was discussed: ow.ly/4KJt50Wasku
Great @astct.bsky.social & @sitcancer.bsky.social Solid Tumor Summit in Chicago yesterday. Important discussions with multiple stakeholders including academia industry and community practice to bring novel cellular therapies to patients with solid tumors.
